Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Press

Showing results (221-230 of 272) with videos related to

Pageof 28
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2015
α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell TransplantationSofia H L Frost, Brian W Miller, Tom A Bäck, et al.
Plos One|March 19, 2015
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft modelsSofia H L Frost, Shani L Frayo, Brian W Miller, et al.
Blood|August 13, 2010
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual diseaseSteven I Park, Jaideep Shenoi, John M Pagel, et al.
American Journal of Hematology|April 4, 2020
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphomaVictor A Chow, Joseph G Rajendran, Darrell R Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescueS Y Liu, J F Eary, S H Petersdorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantationLihua E Budde, Katherine A Guthrie, Brian G Till, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic MalignanciesManuela Matesan, Darrell R Fisher, Roger Wong, et al.
British Journal of Haematology|January 29, 2014
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab eraPeter J Hosein, Jocelyn C Maragulia, Matthew P Salzberg, et al.
Cell|June 21, 2014
A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein induces apoptosis in infected cellsErik Procko, Geoffrey Y Berguig, Betty W Shen, et al.
British Journal of Haematology|January 1, 2019
Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trialLihua E Budde, David Wu, Daniel B Martin, et al.
Pageof 28

Showing results (221-230 of 272) with videos related to

Sort By:
Pageof 28
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2015
α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell TransplantationSofia H L Frost, Brian W Miller, Tom A Bäck, et al.
Plos One|March 19, 2015
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft modelsSofia H L Frost, Shani L Frayo, Brian W Miller, et al.
Blood|August 13, 2010
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual diseaseSteven I Park, Jaideep Shenoi, John M Pagel, et al.
American Journal of Hematology|April 4, 2020
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphomaVictor A Chow, Joseph G Rajendran, Darrell R Fisher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescueS Y Liu, J F Eary, S H Petersdorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantationLihua E Budde, Katherine A Guthrie, Brian G Till, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic MalignanciesManuela Matesan, Darrell R Fisher, Roger Wong, et al.
British Journal of Haematology|January 29, 2014
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab eraPeter J Hosein, Jocelyn C Maragulia, Matthew P Salzberg, et al.
Cell|June 21, 2014
A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein induces apoptosis in infected cellsErik Procko, Geoffrey Y Berguig, Betty W Shen, et al.
British Journal of Haematology|January 1, 2019
Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trialLihua E Budde, David Wu, Daniel B Martin, et al.
Pageof 28